BR0014320A - Composições de substâncias terapêuticas solúveis em tocol - Google Patents

Composições de substâncias terapêuticas solúveis em tocol

Info

Publication number
BR0014320A
BR0014320A BR0014320-0A BR0014320A BR0014320A BR 0014320 A BR0014320 A BR 0014320A BR 0014320 A BR0014320 A BR 0014320A BR 0014320 A BR0014320 A BR 0014320A
Authority
BR
Brazil
Prior art keywords
tocol
soluble
ion
compositions
forming
Prior art date
Application number
BR0014320-0A
Other languages
English (en)
Inventor
Panayiotis Constantinides
Karel Lambert
Alexander Tustian
Andrew Nienstedt
Original Assignee
Sonus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonus Pharma Inc filed Critical Sonus Pharma Inc
Publication of BR0014320A publication Critical patent/BR0014320A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES DE SUBSTâNCIAS TERAPêUTICAS SOLúVEIS EM TOCOL". Composições à base de tocol de compostos farmaceuticamente ativos anififílicos com carga e solúveis em água ou seus precursores com carga são preparadas por formação de um par iónico solúvel em tocol com um composto formador de par iónico de carga oposta capaz de formar um par iónico solúvel em tocol com o composto ativo. Também são apresentados os novos compostos tocoferolsuccinato-aspartato e tocoferolsuccinato-glutamato, que são utilizáveis como compostos formadores de pares iónicos.
BR0014320-0A 1999-09-27 2000-09-27 Composições de substâncias terapêuticas solúveis em tocol BR0014320A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15612899P 1999-09-27 1999-09-27
PCT/US2000/026467 WO2001022937A1 (en) 1999-09-27 2000-09-27 Compositions of tocol-soluble therapeutics

Publications (1)

Publication Number Publication Date
BR0014320A true BR0014320A (pt) 2002-05-28

Family

ID=22558224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014320-0A BR0014320A (pt) 1999-09-27 2000-09-27 Composições de substâncias terapêuticas solúveis em tocol

Country Status (9)

Country Link
US (2) US6479540B1 (pt)
EP (1) EP1216026A1 (pt)
JP (1) JP2003513019A (pt)
KR (1) KR20020059415A (pt)
AU (1) AU7719100A (pt)
BR (1) BR0014320A (pt)
CA (1) CA2385989A1 (pt)
MX (1) MXPA02003203A (pt)
WO (1) WO2001022937A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
AU2001293177A1 (en) * 2000-09-27 2002-04-08 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE60140141D1 (de) * 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
JP5026655B2 (ja) * 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
BR0211673A (pt) * 2001-07-27 2004-07-13 Vital Health Sciences Pty Ltd Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
US6858227B1 (en) 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
ATE487456T1 (de) * 2001-12-13 2010-11-15 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
EP1463487B1 (en) * 2001-12-19 2010-05-19 Research Development Foundation Liposomal delivery of vitamin e based compounds
WO2003068209A1 (en) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
AU2003900200A0 (en) * 2003-01-17 2003-01-30 Vital Health Sciences Pty Ltd Compounds having antiproliferative properties
EP1589964B1 (en) * 2003-01-17 2011-11-23 Vital Health Sciences Pty Ltd. Compounds having anti-proliferative properties
ATE419846T1 (de) * 2003-02-07 2009-01-15 Prometic Biosciences Inc Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
US7919525B2 (en) * 2003-02-14 2011-04-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Radiation protection by gamma-tocotrienol
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP2343045A3 (en) * 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US20050107465A1 (en) * 2003-10-01 2005-05-19 Papas Andreas M. Composition for treating inflammatory bowel disease
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005042539A1 (en) * 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
TWI350183B (en) * 2003-12-31 2011-10-11 Ind Tech Res Inst A liposome and a preparation method
TWI262798B (en) * 2003-12-31 2006-10-01 Ind Tech Res Inst Liposome and drug deliver system
JP4847437B2 (ja) * 2004-03-03 2011-12-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド アルカロイド製剤
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006092024A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
US9168216B2 (en) * 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
CA2659391A1 (en) * 2006-08-03 2008-02-07 Prosensa Technologies B.V. Antibiotic composition
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
EP2196194B1 (en) * 2007-09-10 2017-08-09 M Technique Co., Ltd. Process for producing biological ingesta and biological ingesta obtained thereby
US10251839B2 (en) * 2008-01-22 2019-04-09 Igi Laboratories, Inc. Lipid vesicles derived from olive oil fatty acids
WO2009145619A1 (en) * 2008-04-17 2009-12-03 Prosensa Holding Bv Antibiotic composition
FR2937259B1 (fr) * 2008-10-20 2010-12-24 Commissariat Energie Atomique Vesicules catanioniques, leur procede de preparation et leurs applications
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
EP2335686A1 (en) * 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
WO2012125486A1 (en) * 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
WO2012160559A1 (en) * 2011-05-22 2012-11-29 Rappaport Family Institute For Research In The Medical Sciences Pharmaceutical compositions of d-alpha-tocopheryl acetate
US20130266615A1 (en) * 2012-04-10 2013-10-10 Bin Wu Non-immunogenic delivery vehicle for beta-, gamma-, and delta-tocopherols and methods of using and making same
CN103142479A (zh) * 2013-03-29 2013-06-12 中国药科大学 一种磷脂-维生素e琥珀酸聚乙二醇酯胶束的应用
EP4299058A3 (en) 2014-06-24 2024-03-27 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
CN104523592B (zh) * 2015-01-26 2017-03-15 湖北工业大学 甲泼尼龙醋酸酯注射用自微乳制剂及其制备方法
WO2017093810A2 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
CN106137963B (zh) * 2016-07-27 2019-07-30 武汉科福新药有限责任公司 抗心律失常药物脂肪乳注射液及其制备方法
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
WO2019090030A1 (en) * 2017-11-03 2019-05-09 Prudhomme Robert K Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
EP4670713A1 (en) 2018-05-01 2025-12-31 Chibi, Inc. LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
DE202023001978U1 (de) 2023-09-20 2023-09-29 Penta Phi Eg Formulierung umfassend Coenzym Q10 und Kreatin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US858398A (en) 1902-07-21 1907-07-02 Pittsburg Pneumatic Company Fluid-pressure-operated tool.
US4551332A (en) * 1981-08-05 1985-11-05 Theodore Stillman Vitamin E compositions and methods
US4439432A (en) * 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
US5041278A (en) * 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
DE59409377D1 (de) 1993-10-22 2000-06-29 Hexal Ag Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
KR20070058028A (ko) 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제

Also Published As

Publication number Publication date
AU7719100A (en) 2001-04-30
KR20020059415A (ko) 2002-07-12
WO2001022937A1 (en) 2001-04-05
US6479540B1 (en) 2002-11-12
MXPA02003203A (es) 2004-03-16
CA2385989A1 (en) 2001-04-05
EP1216026A1 (en) 2002-06-26
JP2003513019A (ja) 2003-04-08
US20040053993A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
BR0014320A (pt) Composições de substâncias terapêuticas solúveis em tocol
LU92254I2 (fr) La combinaison de fluticasone et formotérol, ou tous leurs sels ou dérivés pharmaceutiquement acceptables protégés par le brevet de base, y compris lacombinaison de propionate de fluticasone et le fu marate de formotérol
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
TR200402579T4 (tr) Kristalin monohidrat, bunun imalat yöntemi ve bir ilaç maddesinin imalatında kullanımı
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
BR0312464A (pt) Inibidores de tirosina quinases
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
TR200100054T2 (tr) Paroksetin metansülfonat
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
BRPI0508125A (pt) formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica
SE9802208D0 (sv) Novel compounds
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
EP1379508A4 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]